French drug delivery device company Biocorp announced that it has entered into a 10-year strategic partnership with Vitrobio Pharma regarding manufacturing of a new intranasal polymeric product that the company says “acts as a barrier on the nasal surface and prevents contact with pollutants and allergens, while eliminating histamines and harmful proteins through mechanical action, without any side effects” and is “the first drug able to inhibit the harmful effects of pollution causing respiratory distress syndrome.” Biocorp also said that it would invest €600,000 in a new automated production line for the product.
According to Vitrobio’s web site, the company currently makes a filmogen nasal spray for allergic rhinitis that “forms a protective barrier on the nasal mucosa, which minimizes and stops the contact between the nasal mucosa & the allergens.”
Vitrobio Founder and President Ravi Shrivastava commented, “Vitrobio is the first company in the world to develop a treatment against the harmful effects of allergy and pollution on the respiratory tract, especially asthma, without any side effects, representing a global market of several million units. We needed a reliable partner at our side, which is why we chose Biocorp. The geographical proximity of our two production sites is a real advantage and promises a successful long-term partnership to meet this global demand under optimal conditions.”
Biocorp COO Éric Dessertenne said, “We are delighted to sign this new production contract on behalf of third parties. This is a Biocorp’s historical activity and it is still growing strongly. Our collaboration with Vitrobio, a company based in Issoire like us, represents a tremendous industrial and commercial opportunity considering the global challenge of pollution and the risks it poses to everyone’s health. The target market for such a product is promising and several international pharmaceutical companies are already ready to distribute this new product. We are therefore expecting a turnover of at least €1 million per year.”
Read the Biocorp press release.
